Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

The Nucleolus

The Nucleolus

The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Economic evaluation of adjuvant chemotherapy for non-metastatic sarcoma using the real-world data from the French nationwide DEEPSARC study.

Journal of medical economics·2026

Same author

MiT fusions, TSC1-TSC2 divergence, and stem-like programs reveal distinct origins and vulnerabilities in PEComa.

Nature communications·2026

Same author

Hyperprogression after Immune Checkpoint Inhibitors: A Cloudy Phenomenon with Real-life Consequences.

Cancer communications (London, England)·2026

Same author

Validation of the Transcription Association Chromosomal Instability Index Biomarker on RNA Sequencing in Soft Tissue Sarcomas.

JCO precision oncology·2026

Same author

Overall survival of patients with localized soft tissue sarcoma treated with or without adjuvant chemotherapy (DEEPSARC): a real world nationwide retrospective cohort study in France.

EClinicalMedicine·2026

Same author

Beyond Surgical Margins: Fully Mature Tertiary Lymphoid Structures (fmTLSs) Are Predictive Biomarkers for Local Recurrence in Primary Soft-Tissue Sarcomas.

Cancers·2026

Same journal

[Prolonged fever].

La Revue du praticien·2026

Same journal

[Lower gastrointestinal bleeding].

La Revue du praticien·2026

Same journal

[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].

La Revue du praticien·2026

Same journal

[A history of child abuse intervention in the West].

La Revue du praticien·2026

Same journal

[Agranulocytose médicamenteuse].

La Revue du praticien·2026

Same journal

[Patient education in heart failure].

La Revue du praticien·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jan 24, 2026

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

[Sarcoma: a plural entity].

Thibaud Valentin¹, Nicolas Penel², Maud Toulmonde³

¹Oncologie médicale, oncopole Claudius-Regaud, Toulouse, France.

La Revue Du Praticien

|January 23, 2026

Summary

This summary is machine-generated.

Sarcomas are diverse cancers originating from soft tissues or bone. Specialized treatment in centers like Netsarc+ improves patient prognosis, particularly through high-quality surgery.

Keywords:

More Related Videos

The In ovo CAM-assay as a Xenograft Model for Sarcoma

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Related Experiment Videos

Last Updated: Jan 24, 2026

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

The In ovo CAM-assay as a Xenograft Model for Sarcoma

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Area of Science:

Oncology
Pathology

Background:

Sarcomas encompass over 150 histopathological subtypes affecting soft tissues and bone.
Incidence is approximately 70 cases per 100,000 individuals, affecting all age groups.
Most sarcomas are sporadic, with rare predisposing factors.

Purpose of the Study:

To highlight the heterogeneity of sarcoma entities.
To emphasize the importance of specialized treatment centers for improved outcomes.
To underscore the critical role of surgical quality in sarcoma prognosis.

Main Methods:

Review of sarcoma epidemiology and classification.
Analysis of treatment guidelines and outcomes in specialized networks.
Identification of key prognostic factors in sarcoma management.

Main Results:

Sarcomas present a wide range of histological types and anatomical origins.
Early diagnosis and treatment within specialized networks are associated with better prognosis.
Surgical quality is identified as a primary determinant of patient outcomes.

Conclusions:

Effective sarcoma management requires a multidisciplinary approach within expert centers.
High-quality surgical intervention is paramount for improving survival rates in sarcoma patients.
Centralized care in networks like Netsarc+ optimizes sarcoma treatment and prognosis.